Sensient Technologies Corp (SXT): what the price requires

At today's price, Sensient Technologies Corp (SXT) is priced for +15.1% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/SXT

Headline

FieldValue
TickerSXT
CompanySensient Technologies Corp
Sector / IndustryBasic Materials
Current price$113.38/sh
CompositionFlavors & Extracts 53% / Color 47%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed12.8%
Operating margin today14.2%
Margin compression implied-1.4pp
Implied growth15.1%
Multiple paid24x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 8.3% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.6pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.65σ
cohort percentile (of 76 peers)72
sustained it ~5 years at this level50%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.76x5expensive
Earnings3.09x3expensive
Relative1.95x5expensive
Growth1.27x2expensive

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.1%); the inversion above states its own rate.

Per-Model Detail (n=15)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noFCF base $0.0B, growth 6% (input: historical growth), terminal g 4.0%, WACC 8.1%, 6yr projection
DCF Exit MultipleGrowth$89.401.27xyesExit EV/EBITDA: 17.7x / 19.7x / 21.7x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$65.051.74xyesP/E 19.86x (blended: static sector reference 14x + trailing (TTM) 34x), scenarios: 16.6x / 19.9x / 23.1x (bear / base = reference held flat / bull), EV/EBITDA 11.52x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$36.533.10xyesBV/sh $28.56, ROE (TTM) 11.8%, ke 9.3%
Two-Stage Excess ReturnAsset$41.092.76xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$88.681.28xyesRev $1.7B, growth 6% (input: historical growth; tapered), Terminal P/S: 2.4x / 2.9x / 3.4x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$40.682.79xyesEPS $3.39, growth 12% (input: historical EPS growth), PEG=2.89 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$23.824.76xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.19B × (1−25%) / WACC 8.1% → EPV (no growth)
Residual IncomeAsset$42.002.70xyesBV $28.56 + 5yr PV of (ROE (TTM) 11.8% − Kₑ 9.3%) × BV; BV grows 7.7%/yr
Graham NumberAsset$46.682.43xyes√(22.5 × EPS $3.39 × BVPS $28.56) — Graham's conservative floor
EV/EBITDA RelativeRelative$35.763.17xyesEBITDA $0.28B × sector EV/EBITDA 8.0x
FCF YieldEarnings$0.0111338.00xyesFCF $21.9M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.0111338.00xyesSBC-adj FCF $0.01B (FCF $0.02B − SBC $0.01B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings$90.121.26xyesEPS $3.39 × (8.5 + 2×11.6%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$9.0812.49xyesBV $28.56 × (ROIC 2.6% / WACC 8.1%)
P/Sales SectorRelative$58.201.95xyesRevenue $1.66B × sector P/S 1.5x
PEG Fair ValueRelative$59.031.92xyesEPS $3.39 × (PEG 1.5 × growth 11.6% (input: historical EPS growth)) → PE 17.4x
Earnings YieldEarnings$36.653.09xyesEPS $3.39 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$729.5m
Net debt / NOPAT (after-tax)4.12x
Net debt / operating income (pre-tax)3.10x
Interest coverage7.9x
Share count CAGR (dilution)0.3%
Burning cashno

Bullet Takeaways

Bull Case

Start with the uncomfortable fact: the price sits above every family of valuation method, roughly double the peer-multiple reads and nearly triple the asset and earnings-power ones. The bull case is that all of those methods are measuring yesterday's Sensient, and yesterday ended when the FDA set a definitive timeline to phase out petroleum-based synthetic dyes, Red 40, Yellow 5, Blue 1 among them, by the end of 2026. Nearly every packaged food company in America now has a mandatory reformulation project, and Sensient is one of the few suppliers with the palette, the application labs, and the capacity to execute conversions at scale. The 10-K states the position plainly: the company is "accelerating its efforts to enable the conversion of its synthetic food color business in North America (of approximately $100 million in revenue) to natural colors" (accession 0001140361-26-005311). Conversions are not one-for-one swaps; natural colors require more formulation work and more material per application, which is why industry coverage projects a 15% to 20% step-up in natural colorant demand.

The early evidence is in the prints. First-quarter revenue rose 11.1% to $435.8 million with every segment contributing and the Color group growing 18.1%, and management raised full-year GAAP EPS guidance to $3.70 to $3.90 while targeting high single to double digit local-currency revenue and adjusted EBITDA growth. Management is backing the demand signal with capital, stating that with the "sudden legislative change on natural color conversions in the United States, we anticipate our capital expenditures to remain elevated for the next several years as we continue to invest in our natural color capabilities". That is the correct trade: today's depressed free cash flow of $22 million trailing is the cost of owning capacity in a market where customers must convert on a government deadline.

The rest of the portfolio is not idle. The Flavors & Extracts segment lifted its operating margin to "12.8% and 12.2% for 2025 and 2024" respectively per the 10-K (accession 0001140361-26-005311), grinding out mix and pricing gains in a business where the filing describes capabilities spanning "flavor systems, including taste modulation, that are responsive to consumer trends and the processing needs of our food and beverage customers" (same accession). A specialty supplier with pricing power in flavors, a regulatory tailwind in colors, and a balance sheet at just over 3 times operating income has a credible claim on the growth the price is asking for.

Bear Case

For most of its life Sensient was a sleepy specialty-ingredients compounder, the kind of company that grew revenue mid single digits and let the dividend do the talking. What changed was not the business; it was a headline. The FDA's synthetic-dye phase-out turned a quiet colorant supplier into a regulatory-tailwind story, and story stocks get story prices: today's quote implies roughly 16% annual operating-profit growth for five years, from a company whose own guidance, raised, enthusiastic guidance, calls for high single to double digit growth this year. Only about half of comparable fast-growers historically sustained the priced-in pace for five years, and the market is asking Sensient to do it from a standing start of 13.3% operating margins.

The conversion opportunity is real but two-sided, and the company's own risk factors say so: "it is possible that such laws could reduce our revenue if our customers find alternative suppliers or remove color from their products" (accession 0001140361-26-005311). Both halves of that sentence deserve weight. Reformulation events reopen supplier decisions across the industry, giving competitors a shot at accounts Sensient has held for decades, and some customers will simply de-color products rather than pay natural-color premiums. Meanwhile the raw-material side of natural colors is agricultural: the 10-K attributes cost pressure to "atmospheric river events late in the year that disrupted the harvest and production, and higher manufacturing and other costs" (same accession). A colors business built on crops carries weather and harvest risk that petroleum-derived dyes never did, precisely as the company scales it.

The cash flow shows the cost of the pivot. Trailing free cash flow is $22 million against a $4.9 billion market value, with management promising capex stays elevated for several years. Net debt of $729 million sits at about 3.3 times trailing pre-tax operating income with only $39 million of liquid assets, so the conversion buildout is being funded from a balance sheet without much idle cushion. If the FDA timeline slips, if conversions come at lower margins than the market assumes, or if a harvest fails in the wrong year, the growth story loses a chapter while the price has already paid for the whole book.

Valuation

The pattern across methods is unusual for a food-ingredients name: nothing reaches the price. Peer multiples land at roughly half of $115.85 even on a blended 20 times earnings, asset-value reads sit near a third, earnings-power methods lower, and even the forward-growth approaches, which project six years ahead and hold today's 20 times EV/EBITDA flat, come up about 20% short. When every family falls below the quote, the price is a bet beyond what standard frames support, and the bet has a name: the market is capitalizing the FDA-mandated conversion of American food coloring before it shows up in the financials. What the price concretely requires is about 16% annual operating-profit growth for five years from today's 13.3% margin, a pace within what the company has recently delivered but one that only about half of comparable fast-growers historically sustained that long.

The filing anchors the size of the visible opportunity: a North American synthetic color book of "approximately $100 million in revenue" being converted to natural (accession 0001140361-26-005311), inside a company generating $1.66 billion in total revenue, with the Flavors & Extracts segment operating at a disclosed "12.8%" margin in 2025 (same accession). The arithmetic tension is that the conversion book is about 6% of revenue, while the premium over the method reads is far larger, so the price needs conversion economics, share gains, and flavors growth all to compound together. Solvency is serviceable rather than fortress: $729 million of net debt at about 3.3 times trailing pre-tax operating income, interest coverage of 7.3 times, a flat share count, and trailing free cash flow of just $22 million while conversion capex runs hot. The first quarter's 11.1% revenue growth and the raised $3.70 to $3.90 GAAP EPS guide are the early proof points; the price has prepaid for several more years of them.

Catalysts

The FDA's end-of-2026 deadline for phasing out petroleum-based synthetic dyes is the master clock. Every quarter between now and then, packaged-food customers must lock reformulation suppliers, which makes Sensient's Color segment growth rate the single most informative number in each print; it ran 18.1% in the first quarter. The second-quarter report, due on the company's usual mid-July cadence, shows whether conversion bookings are accelerating as the deadline approaches and whether the raised guidance, GAAP EPS of $3.70 to $3.90 with high single to double digit local-currency revenue and adjusted EBITDA growth, absorbs the elevated capital spending management flagged for the natural-color buildout.

The structural markers to track: announced capacity investments in natural color capabilities, which management said will keep capex elevated for several years; the pace at which the roughly $100 million North American synthetic book converts, as disclosed in the February 10-K (accession 0001140361-26-005311); and any state-level or international regulatory follow-through that widens the mandate beyond the United States. Agricultural supply is the recurring wildcard, after harvest disruptions raised costs in the most recent fiscal year, crop outcomes in key botanical inputs feed directly into Color segment margins. The stock has already re-rated on the regulatory story, so the burden each quarter shifts to execution: conversion wins landing as revenue, margins holding through the mix shift, and free cash flow beginning its recovery once the capacity is in place.

Peer Cohorts (Per Segment, With Filing Citations)

Flavors & Extracts (reported)

Color (reported)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Q1 2026 earnings release, April 2026 · FDA phase-out coverage, 2026 · AInvest industry coverage, July 2026 · Q1 2026 earnings call, April 2026

View the full interactive SXT report on boothcheck